Article By:
Elle Investments
Tuesday, May 5, 2020 1:16 PM EDT
The company will need more financing if they don't secure a commercial partner, but phase 3 results demonstrate that linzagolix will be another beneficial option for physicians treating uterine fibroids and endometriosis.
In this article: OBSV
